Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer

• ClinicalTrials.gov Identifier: NCT03162224
• Recruitment Status: Completed
• First Posted: May 22, 2017
• Results First Posted: August 25, 2022
• Last Update Posted: August 25, 2022
• Sponsor: MedImmune LLC
• Information provided by (Responsible Party): MedImmune LLC

Study Description

Brief Summary:

This is a Phase 1b/2a, open-label, multi-center study to evaluate the safety and tolerability, anti-tumor activity, and immunogenicity of MEDI0457 (also known as INO 3112) a HPV Deoxyribonucleic Acid (DNA) vaccine in combination with durvalumab (also known as MEDI4736) which is a human monoclonal antibody directed against Programmed Death Ligand 1 (PD-L1), which blocks the interaction of PD-L1 with PD-1 and Cluster of differentiation 80 (CD80).

An initial three to 12 participants (Safety Analysis Run-in participants) will be enrolled and assessed for safety before additional participants are enrolled.

The initial safety analysis run-in participants along with an approximate total of 50 participants with human papilloma virus associated recurrent or metastatic head and neck squamous cell cancer (HNSCC) will be enrolled in this study and evaluated also for anti-tumor efficacy to MEDI0457 in combination with durvalumab.

Condition or disease	Intervention/treatment	Phase
Head and Neck Cancer; Human Papilloma Virus	Drug: MEDI0457; Device: CELLECTRA®5P device; Drug: Durvalumab	Phase 1; Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 35 participants
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 1b/2a, Multi-Center Open-Label Study to Evaluate the Safety and Efficacy of Combination Treatment With MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients With Recurrent/Metastatic HPV Associated Head and Neck Squamous Cancer
• Actual Study Start Date: June 26, 2017
• Actual Primary Completion Date: March 19, 2021
• Actual Study Completion Date: March 19, 2021

Arms and Interventions

Arm	Intervention/treatment
Experimental: First-line Recurrent/Metastatic (1L R/M) Platinum Non-refractory; Participants with recurrent or metastatic disease and were non-refractory to neoadjuvant/adjuvant platinum based chemotherapy, will receive MEDI0457 7 mg intramuscularly followed by electroporation on Day 1 of Weeks 1, 3, 7, 12, and then every 8 weeks (Q8W) and durvalumab 1500 mg intravenously on Day 1 of Week 4 and then every 4 weeks (Q4W) until disease progression, unacceptable toxicity, or withdrawal of consent, whichever occurs first.	Drug: MEDI0457; MEDI0457 7 mg will be administered intramuscularly followed by electroporation (EP) using CELLECTRA®5P device.; Other Name: INO-3112; Device: CELLECTRA®5P device; MEDI0457 7 mg will be administered intramuscularly followed by EP using CELLECTRA®5P device.; Other Name: CELLECTRA 2000; Drug: Durvalumab; Durvalumab will be administered intravenously at a dose of 1500 mg every 4 weeks.; Other Name: MEDI4736
Experimental: 1L R/M Platinum Refractory; Participants with R/M disease and were refractory to neoadjuvant/adjuvant platinum based chemotherapy, will receive MEDI0457 7 mg intramuscularly followed by electroporation on Day 1 of Weeks 1, 3, 7, 12, and then Q8W and durvalumab 1500 mg intravenously on Day 1 of Week 4 and then Q4W until disease progression, unacceptable toxicity, or withdrawal of consent, whichever occurs first.	Drug: MEDI0457; MEDI0457 7 mg will be administered intramuscularly followed by electroporation (EP) using CELLECTRA®5P device.; Other Name: INO-3112; Device: CELLECTRA®5P device; MEDI0457 7 mg will be administered intramuscularly followed by EP using CELLECTRA®5P device.; Other Name: CELLECTRA 2000; Drug: Durvalumab; Durvalumab will be administered intravenously at a dose of 1500 mg every 4 weeks.; Other Name: MEDI4736
Experimental: Second-line (2L) + R/M; Participants with R/M disease and were treated with 1 or more lines of platinum based chemotherapy, will receive MEDI0457 7 mg intramuscularly followed by electroporation on Day 1 of Weeks 1, 3, 7, 12, and then Q8W and durvalumab 1500 mg intravenously on Day 1 of Week 4 and then Q4W until disease progression, unacceptable toxicity, or withdrawal of consent, whichever occurs first.	Drug: MEDI0457; MEDI0457 7 mg will be administered intramuscularly followed by electroporation (EP) using CELLECTRA®5P device.; Other Name: INO-3112; Device: CELLECTRA®5P device; MEDI0457 7 mg will be administered intramuscularly followed by EP using CELLECTRA®5P device.; Other Name: CELLECTRA 2000; Drug: Durvalumab; Durvalumab will be administered intravenously at a dose of 1500 mg every 4 weeks.; Other Name: MEDI4736

Outcome Measures

Primary Outcome Measures :

1. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) [ Time Frame: Day 1 through 90 days after the last dose of study drug (approximately 45 months) ]
   An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug. There will be no updated results for this outcome measures at the time of end of study.
2. Number of Participants With Abnormal Laboratory Parameters Reported as TEAEs [ Time Frame: Day 1 through 90 days after the last dose of study drug (approximately 45 months) ]
   Any laboratory abnormality during analysis of hematology, clinical chemistry, thyroid function tests, and urinalysis that was new in onset or worsened in severity or frequency from the baseline condition and required therapeutic intervention or diagnostic tests, led to discontinuation of study treatment, had accompanying or inducing symptoms or signs, or judged by the Investigator as clinically significant was recorded as AE. Participants with abnormal laboratory parameters reported as TEAEs are reported.
3. Number of Participants With Abnormal Electrocardiogram (ECG) Reported as TEAEs [ Time Frame: Day 1 through 90 days after the last dose of study drug (approximately 45 months) ]
   Participants with ECG abnormalities reported as TEAEs are reported.
4. Number of Participants With Abnormal Vital Signs and/or Physical Examination Reported as TEAEs [ Time Frame: Day 1 through 90 days after the last dose of study drug (approximately 45 months) ]
   Vital sign assessment included body temperature, respiration rate, pulse oximetry, blood pressure, heart rate, and weight. Participants with abnormal vital sign and/or abnormal physical examination reported as TEAEs are reported.
5. Number of Participants Who Received Any Concomitant Medications During the Study [ Time Frame: Day 1 through 90 days after the last dose of study drug (approximately 45 months) ]
   Participants who received concomitant medications which were ongoing at the start of treatment or started after the study treatment are included.
6. Number of Participants With Shift >=3 Changed From Baseline in Eastern Cooperative Oncology Group Performance (ECOG) Status [ Time Frame: Day 1 through 90 days after the last dose of study drug (approximately 45 months) ]
   Participants with shift >=3 changed from baseline in ECOG status are reported. ECOG performance status is used by doctors and researchers to assess how a participant's disease is progressing, assess how the disease affects the daily living activities of the participant and determine appropriate treatment and prognosis. The scores are: 0 = Fully Active, able to carry out all pre-disease performance without restrictions; 1 = Restricted activity but ambulatory and able to carry out light work or work of a sedentary nature; 2 = Ambulatory and capable of self-care but unable to carry out work activities; 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4 = Completely Disabled, unable to carry out any self-care and totally confined to bed or chair; 5 = Dead.
7. Percentage of Participants With Objective Response by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 in Response-evaluable Population [ Time Frame: Day 1 through end of study (approximately 45 months) ]
   The objective response is defined as confirmed complete response (CR) or confirmed partial response (PR) based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) guidelines. The CR is defined as disappearance of all target and non-target lesions, no new lesions, and normalization of tumor marker level. The PR is defined as >= 30% decrease in the sum of the diameters of target lesions compared to baseline and no new non-target lesion. A confirmed CR or PR is defined as 2 CRs or 2 PRs that were separated by at least 4 weeks with no evidence of progression or not evaluable response in-between. Percentage of participants with objective response is reported.

Secondary Outcome Measures :

1. Percentage of Participants With Objective Response by RECIST Version 1.1 in As-treated Population [ Time Frame: Day 1 through end of study (approximately 45 months) ]
   The objective response is defined as confirmed CR or confirmed PR based on RECIST v1.1 guidelines. The CR is defined as disappearance of all target and non-target lesions, no new lesions, and normalization of tumor marker level. The PR is defined as >= 30% decrease in the sum of the diameters of target lesions compared to baseline and no new non-target lesion. A confirmed CR or PR is defined as 2 CRs or 2 PRs that were separated by at least 4 weeks with no evidence of progression or not evaluable response in-between. Percentage of participants with objective response is reported.
2. Percentage of Participants With Objective Response by Immune-related RECIST (irRECIST) in Response-evaluable Population [ Time Frame: Day 1 through end of study (approximately 45 months) ]
   The objective response is defined as confirmed CR or confirmed PR based on irRECIST v1.1 guidelines. The irCR is defined as disappearance of all target and non-target lesions, no new lesions, and normalization of tumor marker level. The irPR is defined as >= 50% decrease in the sum of the diameters of target lesions compared to baseline and no new non-target lesion. A confirmed irCR or irPR is defined as 2 irCRs or 2 irPRs that were separated by at least 4 weeks with no evidence of progression or not evaluable response in-between. Percentage of participants with objective response is reported.
3. Percentage of Participants With Objective Response by irRECIST in As-treated Population [ Time Frame: Day 1 through end of study (approximately 45 months) ]
   The objective response is defined as confirmed CR or confirmed PR based on irRECIST v1.1 guidelines. The irCR is defined as disappearance of all target and non-target lesions, no new lesions, and normalization of tumor marker level. The irPR is defined as >= 50% decrease in the sum of the diameters of target lesions compared to baseline and no new non-target lesion. A confirmed irCR or irPR is defined as 2 irCRs or 2 irPRs that were separated by at least 4 weeks with no evidence of progression or not evaluable response in-between. Percentage of participants with objective response is reported.
4. Disease Control Rate (DCR) at Week 16 by RECIST Version 1.1 in Response-evaluable Population [ Time Frame: Week 16 ]
   The DCR is defined percentage of participants with CR, PR, or stable disease (SD) at 16 weeks based on RECIST v1.1 guidelines. A CR is defined as disappearance of all target and non-target lesions, no new lesions, and normalization of tumor marker level. A PR is defined as >= 30% decrease in the sum of longest diameters of target lesions compared to baseline and no new non-target lesion. The SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression, taking as reference the smallest sum longest diameter since the study treatment started, and persistence of one or more non-target lesion(s) or / and maintenance of tumor marker level above the normal limits.
5. DCR at Week 16 by RECIST Version 1.1 in As-treated Population [ Time Frame: Week 16 ]
   The DCR is defined percentage of participants with CR, PR, or SD at 16 weeks based on RECIST v1.1 guidelines. A CR is defined as disappearance of all target and non-target lesions, no new lesions, and normalization of tumor marker level. A PR is defined as >= 30% decrease in the sum of longest diameters of target lesions compared to baseline and no new non-target lesion. The SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression, taking as reference the smallest sum longest diameter since the study treatment started, and persistence of one or more non-target lesion(s) or / and maintenance of tumor marker level above the normal limits.
6. Progression Free Survival (PFS) [ Time Frame: Day 1 through end of study (approximately 45 months) ]
   The PFS is defined as the time from the date of start of study treatment until the documentation of disease progression based on RECIST version 1.1 or death due to any cause, whichever occurs first. The progressive disease is defined at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started, the appearance of one or more new lesions, or unequivocal progression of existing non-target lesions. Participants who were not progressed or died at the time of the analysis were censored at the time of the latest date of assessment from their last evaluable RECIST version 1.1 assessment. The PFS was estimated using Kaplan-Meier method.
7. Overall Survival (OS) [ Time Frame: Day 1 through end of study (approximately 45 months) ]
   Overall survival is defined as the time from the date of start of study treatment until death due to any cause. Any participant not died at the time of analysis was censored based on the last recorded date on which the participant was known to be alive. The OS was estimated using Kaplan-Meier method.
8. Number of Participants With Positive Anti-Drug Antibodies (ADA) to Durvalumab [ Time Frame: Pre-dose (up to 60 minutes prior to durvalumab administration) on Week 4, Week 8, and Week 16 ]
   Number of participants with positive ADA titer to durvalumab are reported. ADA prevalence is defined as ADA positive at any point (baseline and post-baseline); persistent positive is defined as ADA positive at Week 16, and transient positive is defined as positive at Week 8 but not at Week 16, regardless of baseline positivity.
9. Serum Concentrations of Durvalumab [ Time Frame: Pre-dose (up to 60 minutes prior to durvalumab administration) on Week 4, Week 8, and Week 16 ]
   Serum concentrations of durvalumab is reported.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 99 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Male and female participants 18 years and older
2. Histologically or cytologically confirmed diagnosis of HNSCC associated with HPV by a p16 immunohistochemistry (IHC) assay or HPV-16 or HPV-18 positive by nucleic acid testing.
3. Recurrent or metastatic disease that has been treated with at least one platinum-containing regimen and lacking a curative treatment option.
4. Participants who are platinum ineligible may be enrolled if they have received and failed an approved treatment and lack a treatment option with curative potential.

Exclusion criteria:

1. Any concurrent chemotherapy, immune-mediated therapy or biologic or hormonal therapy for cancer treatment Active or prior documented autoimmune disease with some exceptions.
2. Current or prior use of immunosuppressive medication within 14 days prior to first study dose, with the exception of intranasal and inhaled corticosteroids or systemic corticosteroids at doses not to exceed 10 mg/day of prednisone or equivalent. Steroids as premedication for hypersensitivity reactions due to radiographic contrast agents are allowed.
3. No prior exposure to immune-mediated therapy defined as prior exposure to T-cell and natural killer cell directed therapy (e.g., anti-PD-1, anti-PD-L1, anti-CD137, and anti-CTLA4, etc).

Contacts and Locations

Locations

United States, California

Research Site

San Francisco, California, United States, 94115

United States, Florida

Research Site

Orlando, Florida, United States, 32806

United States, Georgia

Research Site

Atlanta, Georgia, United States, 30308

United States, Indiana

Research Site

Indianapolis, Indiana, United States, 46202

United States, Maryland

Research Site

Baltimore, Maryland, United States, 21201

Research Site

Baltimore, Maryland, United States, 21287

United States, Michigan

Research Site

Detroit, Michigan, United States, 48201

United States, Minnesota

Research Site

Minneapolis, Minnesota, United States, 55414

United States, Missouri

Research Site

Saint Louis, Missouri, United States, 63110

United States, New Jersey

Research Site

Morristown, New Jersey, United States, 07960

United States, New York

Research Site

Bronx, New York, United States, 10461

United States, North Carolina

Research Site

Winston-Salem, North Carolina, United States, 27157

United States, Ohio

Research Site

Columbus, Ohio, United States, 43210

United States, Pennsylvania

Research Site

Philadelphia, Pennsylvania, United States, 19104

Sponsors and Collaborators

MedImmune LLC

Investigators

• Study Director: MedImmune LLC; Study Director

  Study Documents (Full-Text)

Documents provided by MedImmune LLC:

Study Protocol  [PDF] March 17, 2021

Statistical Analysis Plan  [PDF] June 21, 2021

More Information

Additional Information:

D8860C00005 SAP redacted 

CSP Redacted 

CSR Synopsis Redacted 

• Responsible Party: MedImmune LLC
• ClinicalTrials.gov Identifier: NCT03162224
• Other Study ID Numbers: D8860C00005
• First Posted: May 22, 2017
• Results First Posted: August 25, 2022
• Last Update Posted: August 25, 2022
• Last Verified: August 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes
• Plan Description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
• Supporting Materials: Study Protocol; Statistical Analysis Plan (SAP)
• Time Frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
• Access Criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
• URL: https://astrazenecagroup-dt.pharmacm.com/DT/Home

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: Yes
• Product Manufactured in and Exported from the U.S.: No

Keywords provided by MedImmune LLC:

Head and Neck Squamous Cell Carcinoma; Oropharyngeal Cancer; HPV; Human Papilloma Virus; Cancer Immunotherapy; Check point inhibitors; PD-L1 inhibitor; Recurrent or Metastatic Cancer; Durvalumab; MEDI0457; Antineoplastic agents; Neoplasms

Additional relevant MeSH terms:

Head and Neck Neoplasms; Papilloma; Neoplasms by Site; Neoplasms; Neoplasms, Squamous Cell; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Durvalumab; Antineoplastic Agents, Immunological; Antineoplastic Agents